Castle Biosciences (CSTL) - Long-Term Debt to Capital

The price trend for Castle Biosciences (CSTL) shown on this GURU.Markets chart helps assess the company's expansion into the B2B molecular skin pathology analysis segment, where the indicator stands at 0.07. The business relies on specialized express delivery of biosamples to laboratories, while profitability is constrained by strict US insurance limits, despite its status as the gold standard for melanoma detection.

Reagent shortages and disruptions in international testing due to geopolitics create risks for the operational resilience of Castle Biosciences (CSTL). By analyzing the long-term debt-to-equity ratio, an investor determines the proportion of loans with maturities exceeding one year within the equity structure, which allows them to distinguish strategic development from attempts to mask a crisis with borrowed funds and avoid a sudden freeze of assets.